30-Second Explanation
Lilly earns money from medicines, but the business is larger than discovering a promising molecule. A product must demonstrate an acceptable benefit-risk profile for a defined use, receive regulatory permission, be manufactured consistently and reach patients through a functioning healthcare and payment system.
Those requirements connect different organizations. Researchers develop evidence; regulators evaluate applications; healthcare professionals decide about care; pharmacies and providers handle medicine; insurers, public programs and patients participate in payment. Lilly influences many parts of that system without controlling all of them.
The company must also replace and extend its portfolio. Scientific failure, competing treatments and changing exclusivity can weaken a product's economics. Current successes fund work whose outcome remains uncertain, including internal research, licensed compounds and acquired development programs.
What Lilly Actually Does
Turns scientific ideas into testable medicines
Lilly's research groups study biological mechanisms and potential ways to alter them. A target can be scientifically interesting without producing a medicine that works acceptably in people. Development therefore has to test the proposed intervention rather than assume a good laboratory result proves clinical value.
The company combines internal discovery with external opportunities. A license provides defined rights; an acquisition can add a team and a pipeline; a collaboration divides responsibilities among organizations. These are different ways of obtaining capability and carry different obligations.
Builds evidence for particular uses
Clinical development asks questions about a defined population, treatment setting and outcome. The same molecule can be studied for more than one condition, with separate evidence and regulatory decisions. A positive result in one setting does not establish approval in another.
This distinction is visible in the current portfolio. Tirzepatide appears in more than one brand, while some later uses involve additional evidence. Orforglipron has an approved obesity product and a separately described diabetes-development path. The molecule, brand, indication and study program are related but not interchangeable. [S5][S6][S7][S30]
Makes and supplies regulated products
Manufacturing includes producing an active ingredient and turning it into the form that can be supplied. Formulation, filling, device components, packaging and release testing can each become operational requirements. A successful molecule is not useful to a patient if the finished product is unavailable.
Lilly operates its own facilities and uses external participants. Capacity has to fit the product and meet quality requirements; another building or production line does not instantly become qualified supply. Its manufacturing and quality descriptions connect production controls with the consistency required of medicine. [S26]
Commercializes within a healthcare system
Commercialization includes explaining evidence, obtaining access and supplying the product through appropriate channels. It does not mean selling an unrestricted consumer item. A prescription, an insurance decision and a pharmacy transaction involve different responsibilities.
Safety work also continues after launch. Lilly describes ongoing pharmacovigilance and processes for communicating product concerns. An initial approval is a significant event, not the end of the evidence and safety responsibilities associated with the medicine. [S27]
Major Products and Their Different Jobs
Diabetes, obesity and related risk
Mounjaro contains tirzepatide and has a diabetes-centered US label that now also includes cardiovascular-risk reduction for a defined adult population. Its role is not accurately summarized by calling every prescription a weight-loss transaction. [S6]
Zepbound contains the same active ingredient but has its own approved-use boundaries for weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Sharing a molecule does not make the two brands identical commercial franchises or create permission to combine them. [S7]
Foundayo contains orforglipron, an oral GLP-1 receptor agonist. Its April 2026 US obesity approval added a different product format and development history; it is not oral tirzepatide. Lilly obtained development and commercialization rights through a Chugai license, illustrating the role of external scientific origin within the portfolio. [S5][S8][S1]
Jardiance contains empagliflozin and is part of Lilly's alliance with Boehringer Ingelheim. Its product role spans defined diabetes, cardiovascular, heart-failure and chronic-kidney-disease uses. The alliance affects how the parties share responsibilities and economics, so all global product sales cannot be assigned to Lilly as though no partner exists. [S29][S1]
Lilly's insulin portfolio performs another job. Products such as Humalog and Humulin supply insulin; they are not simply older versions of incretin medicines. Delivery forms and formulations differ, with practical implications for manufacturing, distribution and safe use. [S4][S28]
Oncology
Verzenio contains abemaciclib, a CDK4/6 inhibitor used in defined breast-cancer settings. Its commercial role depends on clinical setting, combinations and evidence, rather than an undifferentiated promise to treat all cancer. [S9]
Inluriyo contains imlunestrant, an estrogen-receptor-directed medicine with a biomarker-defined advanced-breast-cancer label. It has a distinct mechanism and product identity, even where it is used in a combination involving abemaciclib. The patient-selection requirement is part of the care and commercial system. [S10]
Jaypirca contains pirtobrutinib, a BTK-directed medicine in blood cancers. Its labels distinguish populations and treatment settings, including a separately conditioned accelerated-approval indication. One brand can therefore have several regulatory evidence boundaries rather than one universal approval status. [S11]
The wider oncology portfolio also includes products such as Retevmo. That breadth connects internal development with acquired and partnered science; it does not imply that every cancer product shares the same biological target or development history. [S4][S19]
Immunology
Taltz targets IL-17A in specified skin and joint-related conditions. Ebglyss targets IL-13 for a defined atopic-dermatitis population. Omvoh targets IL-23 in adult inflammatory bowel disease. Their different targets, care pathways and administration requirements make them separate products, not interchangeable versions of one antibody. [S13][S14][S15]
These franchises compete within chronic-care systems where clinicians and patients assess response and tolerability, while payers evaluate coverage. A treatment can have a meaningful clinical role and still face substantial access competition. A broad immunology presence helps Lilly address several needs without making each sale automatic.
Neuroscience
Kisunla contains donanemab, an amyloid-directed Alzheimer's medicine. Its role includes diagnosis, confirmation of relevant pathology, infusion capacity and monitoring. The evidence supports slowing decline in the studied setting, not a cure or restoration of every lost function. Its ARIA boxed warning is a material part of the product's operating context. [S12][S33]
Other neuroscience products and investigational programs address different problems. For example, migraine treatment does not use the same delivery and monitoring system as an Alzheimer's infusion. “Neuroscience” is an area of activity, not one unified medicine or patient pathway.
One Reportable Segment, Several Therapeutic Areas
Lilly reports a single pharmaceutical segment. The therapeutic areas help explain its science and commercial organization, but they are not interchangeable with separately reported operating segments. Product-level disclosures answer different questions from the consolidated segment statements. [S1]
That structure reflects shared research, supply and corporate capabilities across medicines. It does not mean all products have the same margins, development risk, demand or life cycle. A large established product and an early-stage acquired candidate occupy very different positions in the business.
The distinction is useful when considering growth. A changing product mix can alter the company's economics even while the segment count remains one. Conversely, creating more therapeutic headings in a presentation does not itself create more independent businesses or reported revenue streams.
Who Uses the Products—and Who Makes the Decisions?
Patients are the people receiving treatment, but they are not the only decision-makers. Clinicians evaluate medical suitability and manage care. Hospitals, infusion centers and pharmacies perform different parts of delivery. Caregivers may help patients navigate treatment and administration.
The commercial decision also involves payers. An insurer can define coverage requirements, a public program can negotiate or set reimbursement rules, and an employer can influence benefits through its health plan. Those choices affect access without replacing a clinician's responsibility for an individual treatment decision.
Some medicines pass through a retail or specialty pharmacy; others are administered in a provider setting. That difference changes inventory, reimbursement and operating requirements. A company cannot treat all medicine access as a single online checkout problem.
The direct customer purchasing from Lilly may also be a wholesaler or another intermediary rather than the person receiving the medicine. Understanding the user, prescriber, purchaser and payer as separate roles is necessary to explain how demand turns into reported sales.
Who Pays Lilly?
Medicine payments move through contractual channels. A distributor or provider may purchase supply, while an insurer or public program funds part of the patient's care. Rebates, discounts and other adjustments influence the amount the manufacturer ultimately retains.
As a result, a published list price is not equivalent to Lilly's net revenue per prescription, and the patient's payment is not automatically the manufacturer's entire receipt. Different cash flows can attach to the same course of treatment.
Lilly's product revenue also includes alliance arrangements. Jardiance is a useful example because the partner relationship changes who commercializes and how the economics are shared. A product's broad market size and one company's reported revenue from it are different measures. [S1][S2]
These distinctions make access a business-model issue. A medicine's biological effect creates potential clinical value; actual revenue depends on whether eligible patients can obtain it through a supported, funded and functioning delivery pathway.
How Lilly Makes Money
Approved products earn revenue over their commercial lives
A successful medicine can generate repeated sales as patients begin or continue appropriate treatment. That relationship differs from a guaranteed subscription: use can change because of response, tolerability, clinical decisions, coverage, affordability or another therapy.
The company needs enough continuing value to support manufacturing, selling, safety and future research. A product with strong demand can still face pricing pressure or constrained access. Its economic life is determined by more than the date it first received approval.
Product extensions can broaden a supported use
Further evidence can support additional indications, populations or combinations. This can expand the product's role without requiring a completely new molecule. It also creates additional development work and does not guarantee the same result across every setting.
Zepbound's December 2024 OSA approval illustrates a specific expansion beyond its original weight-management approval. It applied to moderate-to-severe OSA in adults with obesity, not to every sleep disorder. [S34]
Partnerships can share cost, rights and returns
A license can bring a molecule into Lilly's development system while preserving milestone or royalty rights for its originator. A co-commercialization arrangement can allocate territories and responsibilities between companies. Neither should be confused with buying a wholly owned product outright.
Orforglipron's Chugai origin and Jardiance's Boehringer alliance illustrate different arrangements. Lilly can contribute clinical development, manufacturing and commercial capability while another organization retains a defined part of the economics. [S1]
Why Price and Volume Can Move in Opposite Directions
For the year ended December 31, 2025, Lilly reported $65.179 billion of revenue and $20.640 billion of net income. Revenue comprised $60.958 billion of net product revenue and $4.221 billion of collaboration and other revenue. These categories show why the consolidated total cannot be interpreted as only wholly owned medicine sales. [S1]
Net income is not the same as cash available from every prescription. Research, production, commercial expenses, taxes and other items affect the result, while cash flows also reflect timing and investment. The full-year figures provide historical scale; they are not FY2026 results or a valuation of the pipeline.
In Q2 2026, Lilly reported approximately $23.0 billion in revenue, up 48% from the corresponding prior-year quarter. The company attributed the change to higher volume, partially offset by lower realized prices. These are results for a particular quarter, not a guarantee of future growth. [S3]
The mechanism is important beyond the headline. Broader reimbursement or a lower effective price can make a medicine accessible to more patients. Additional volume can then offset some price reduction, depending on the size and timing of both changes.
That outcome is not automatic. Lower price without sufficient demand can reduce revenue; additional demand without available supply can go unmet. A reported growth rate is the net result of several moving parts, including product mix and geography.
For the customer system, access can improve while the manufacturer's revenue per unit declines. For the company, more people using a product does not mean each prescription earns the same amount as before. Both can be true within the same reporting period.
Manufacturing Is a Strategic Constraint
Manufacturing has several linked stages. An active ingredient must be produced, processed and tested; a finished product may require sterile filling and a delivery device; the final package must reach the appropriate channel. Increasing one stage can reveal a shortage or limitation in another.
Lilly's investment commitments address this broader system. Its Q2 2026 release included an additional Indiana manufacturing commitment, while the filings describe expansion and the use of outside supply participants. An announced investment and released commercial output are different milestones. [S3][S2]
The timing creates a capital-allocation challenge. Waiting for every unit of demand to be certain can leave supply arriving too late. Building ahead can create exposure if demand, the product mix or the development outcome changes. Product-specific qualification also limits how easily capacity can be switched to a different medicine.
The commercial consequence is that manufacturing cannot be separated from product strategy. Evidence and approval create the opportunity to supply a medicine; dependable production determines how much of that opportunity can be served.
Distribution and LillyDirect
LillyDirect connects selected medicines with prescription support and pharmacy fulfillment options. Its current service describes help with the prescription process, savings and access, while separate providers retain independent clinical judgment. It is not permission to obtain prescription medicine without a suitable prescription. [S16]
The business purpose is to reduce practical friction between an appropriate prescription and obtaining the product. That friction can involve coverage, availability, dispensing and the patient's understanding of the process.
The platform does not remove every intermediary or make every product available under identical terms. Pharmacy operations, independent healthcare services and insurance decisions remain different functions. Connecting them through a branded service does not make Lilly the clinician making every care decision.
It also creates a different customer relationship from supplying only through conventional channels. Lilly can make an access route more visible while still depending on clinical and dispensing organizations to carry out their responsibilities.
What Lilly Depends On
Evidence that survives further testing
Early scientific promise has to hold up in later studies. A biomarker change may support a hypothesis without proving a lifetime clinical outcome. Verve's early gene-editing program illustrates why a development objective and an established benefit remain distinct. [S22]
Regulatory permission for the particular use
An approval is defined by product, population, indication and jurisdiction. A study in a new setting can remain investigational even where the same molecule is already sold elsewhere. Current labels, rather than a generic pipeline status, define the authorized uses observed at review.
Supply and quality systems
The company depends on its own operations and external materials, components and production services. Finished medicine must meet its specifications consistently. More nominal capacity does not compensate for a quality problem or an unavailable component at another stage. [S26]
Healthcare access and operating capacity
A patient may need a diagnosis, testing, an appointment, a supported pharmacy or an infusion site. The payment system must also permit access. A large population with a condition is not the same as an immediately reachable population of product users.
Continuing trust
Clinical evidence, product quality and accurate communication support the willingness of professionals and patients to use a medicine. Safety monitoring can reveal information after launch that changes the product's use or commercial position. Ongoing pharmacovigilance is therefore part of the business rather than a separate public-relations exercise. [S27]
Who Depends on Lilly?
Patients and care teams depend on reliable supply of products they use. Pharmacies and providers depend on appropriate product information and delivery. Research partners can depend on Lilly to fund and execute further development of licensed or acquired programs.
Suppliers and manufacturing partners can also commit resources around expected Lilly demand. The relationship runs both ways: Lilly needs the capability, and the partner may build capacity or allocate staff to serve it.
None of these dependencies makes the company the sole source of all care in its therapeutic areas. Alternative medicines, different clinical approaches and changing health-system decisions remain relevant. Dependency concerns the actual product or program, not a blanket claim that a whole disease area belongs to one company.
Competition Happens at Several Layers
Named competitors address particular clinical markets
Novo Nordisk's semaglutide franchises, including Ozempic and Wegovy, provide direct competitive context in diabetes, obesity and related supported uses. The comparison involves product evidence, format, supply and access; it is not enough to count hormone targets or compare headline results from unrelated trials. Each label still defines its own population and role. [S74]
In breast cancer, Novartis's Kisqali is another CDK4/6 medicine with evidence in specified early and advanced settings. Its presence helps explain why Verzenio operates within a clinical and commercial choice set rather than owning every hormone-sensitive breast-cancer prescription. The products' eligibility, combinations and safety requirements are not identical. [S75][S9]
In atopic dermatitis, Sanofi and Regeneron's Dupixent provides a named alternative in an established treatment market. Ebglyss must earn its place through its own evidence and access arrangements. Participation in the same disease area does not establish that the products act on exactly the same target or are interchangeable. [S76][S14]
In early Alzheimer's disease, Eisai and Biogen's Leqembi is a separate amyloid-directed medicine. Competition involves diagnosis, evidence, delivery, monitoring and health-system capacity, not merely which antibody reached the market first. Listing the alternative does not provide a patient-specific ranking or permission to substitute one treatment for another. [S77][S12]
Scientific and clinical differentiation
Medicines can compete on benefits, risks, evidence in a particular population and practical delivery. A mechanism that looks similar at a high level can still lead to a different clinical profile. Cross-trial headline comparisons alone do not establish which treatment is best for an individual patient.
Access and economic value
Payers compare the clinical evidence with budgets and alternatives. Negotiated access can influence how much of the eligible population can receive a medicine and the manufacturer's effective price. Clinical approval and reimbursement are different decisions.
Treatment systems
An oral medicine, an injectable product and an infusion can place different demands on patients and providers. Convenience can matter, but it does not erase safety, effectiveness or eligibility requirements. A new format can expand choice without displacing every existing therapy.
Future portfolio capability
Companies also compete to discover, license or acquire the next generation of programs. The winner of a transaction still has to develop what it bought. Acquiring a clinical-stage business is a resource commitment, not proof that its candidates will become successful products.
Leadership and Resource Allocation
David Ricks became CEO in January 2017 and chair in June 2017. His role includes corporate priorities, capital commitments and the relationships connecting development, manufacturing and access. Company achievements during his tenure remain the work of teams and partners rather than proof of personal invention. [S17]
Daniel Skovronsky is Chief Scientific and Product Officer and president of Lilly Research Laboratories. The combined role spans research/development and specified product responsibilities. His official history also connects Lilly to the acquired Avid organization, demonstrating one way external capability entered its leadership system. [S18]
Resource allocation has to balance products already earning revenue with programs that may fail. Manufacturing investment supports expected supply, while clinical investment tests whether the future product deserves to exist. Acquisitions and licenses add options but also compete for money, staff and management attention.
The structural challenge is to keep those commitments coordinated. A company can have strong science but insufficient supply, or available capacity but a disappointing development outcome. Management has to consider the connected system rather than optimize one function alone.
Major Acquisitions and Capability Changes
Loxo Oncology joined Lilly in February 2019. The transaction added precision-oncology programs and expertise around genomically defined cancers. The acquired business had its own licensing relationships, so ownership did not make every associated medicine an exclusively Lilly-commercialized product. [S19]
Verve Therapeutics joined in July 2025. Its cardiovascular gene-editing programs extended Lilly's development possibilities beyond repeated conventional treatment. Those possibilities remained clinical-development programs; buying the company did not establish lifelong benefit or product approval. [S20][S21][S22]
Centessa Pharmaceuticals joined in June 2026, adding clinical-stage orexin work for sleep-wake disorders. It expanded neuroscience capability in a different way from Alzheimer's antibody development. The relevant transfer was a pipeline and organization, not an already proven cure for every sleep disorder. [S23][S24]
Other transactions expanded the portfolio further. Q2 reporting described additional business-development activity, and the September 2026 AtaiBeckley completion added another neuroscience direction. These events demonstrate a wider set of external bets rather than a company relying exclusively on one internal research path. [S3][S35]
History and Turning Points
From an Indianapolis medicine business to the current company
Colonel Eli Lilly founded the predecessor drug business in Indianapolis in 1876. The current company incorporated in Indiana in 1901 to succeed that business. Founding the original operation and incorporating the present legal entity are different historical events. [S1]
A long-standing insulin business
Insulin became an important part of the company's product identity, with later products and delivery forms extending the portfolio. Humalog's US prescribing information records initial approval in 1996. That product history helps explain why today's cardiometabolic business is broader than the recent obesity expansion. [S28]
2017–2019: leadership and precision-oncology expansion
2022–2024: new product roles require new care systems
Mounjaro's initial US approval came in 2022, followed by Zepbound's weight-management approval in 2023. Kisunla and Zepbound's OSA indication added different clinical and operating requirements in 2024. The same company could serve a pharmacy-centered chronic-care product and a diagnosis/infusion/monitoring system without those becoming identical businesses. [S6][S32][S33][S34]
2025–2026: broader science and capacity commitments
What Most People Miss
Two brands can share a molecule without sharing the whole business pathway
A prescription is not a completed sale or a treatment outcome
The patient still needs access and supply. Payment may involve several organizations, and use may not continue. The sequence from an appropriate prescription to a sustained clinical outcome includes more steps than a demand headline suggests.
An acquired molecule can still owe economics to another company
Scientific origin, development rights, manufacturing and commercialization can sit with different organizations. Licenses and alliances preserve those distinctions. A brand appearing in Lilly's portfolio is not proof that every dollar of its global economics belongs to Lilly. [S1]
More pipeline entries do not mean more approved products
A single molecule can appear in several indication programs. Each still has to establish its own evidence and regulatory status. The pipeline is a map of development work, not an inventory of guaranteed future revenue. [S30]
Current Limits and Open Outcomes
The completed Q2 2026 reporting shows substantial product-driven growth; it does not settle every future program's outcome. Retatrutide's development plans, Verve's gene-editing objectives and Centessa's orexin programs have different evidence stages and risks. [S3][S22][S24]
Product success also creates concentration. Strong demand for a small set of medicines can make manufacturing and access decisions especially consequential. Broadening the pipeline can create additional possibilities without immediately diversifying current revenue to the same degree.
The company's continuing task is to translate scientific and commercial opportunity into dependable, appropriate use while renewing the portfolio. Approval, capacity, coverage and future innovation are separate achievements that have to remain connected.
Evidence
Annual and quarterly filings establish legal identity, reporting and contractual boundaries. Current product labels establish US indications and material limits observed at review. FDA releases establish dated regulatory events. Official role biographies and transaction completions establish leadership and acquired capability without inventing personal causation. [S1][S2][S5][S6][S7][S8][S9][S10][S11][S12][S13][S14][S15][S17][S18][S19][S21][S24]
Connected Entities
The shared Pharmaceuticals industry explains the company-neutral system. How Lilly Turned Obesity Demand into a Manufacturing System and How Lilly Renews Its Medicine Portfolio explain separate causal transformations rather than repeat the company overview.